Four dividend ETFs deliver yields above 7% by owning assets directly, avoiding covered-call options that cap upside. The Alerian MLP ETF leads with a 7.6% yield and consistent quarterly payout increases. The VanEck BDC Income ETF offers the highest yield at 12.6%, focusing on private credit. Other funds like Invesco KBW Premium Yield Equity REIT ETF and Global X SuperDividend ETF provide monthly income but have seen payout declines. These ETFs suit income investors seeking high yields but come with varying risks such as concentration, price erosion, and credit risk.
The story on dividend ETFs yielding over 7% provides context for income-focused investments. For readers following US stocks on Pluang, here is the market snapshot as of Nov 02, 2026 19:41 WIB: out of 150 priced US stocks, 105 rose and 41 fell today. Notable movers include RIVN (Rivian Automotive, Inc.) at USD 12.58 with a 3.45% increase, BABA (Alibaba Group) at USD 101.31 up 3.41%, and NOK (Nokia Corp) at USD 8.81 rising 3.28%.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
